9 June 2026
In plain English
The US government published the paperwork doctors need to prescribe weight-loss drugs like Ozempic (called GLP-1s) through Medicare's new $50-a-month program launching July 1. The form narrows eligibility: patients must have sleep apnea, liver disease, diabetes, or heart disease — not just obesity. This was the missing piece pharmacies were waiting for, and its arrival 22 days before launch improves enrollment readiness. Barque nudged its estimate that fewer than one million seniors will enroll this year.
The FDA's advisory panel on experimental drugs called peptides (short protein fragments used for recovery and longevity) still has nine of twelve seats empty after six months. The longer that holds, the more likely the three career scientists defer decisions to a better-staffed session.
Signal detail
44 days to PCAC. Zero vacancy appointments in 26+ weeks. Roster unchanged: 3 voting (Fensky, Rebello, Serumaga) + 1 industry liaison, no chair, of 12 authorized. Oral presentation deadline June 30 (21 days). Post-ADA media window opens today — pharma press will begin rotating to PCAC coverage. No new evidence.
44 days to PCAC. Same vacancy dynamics. Binary-outcome structural concern persists: 3-member committee reviewing 7 peptides over 2 days favors all-pass or all-defer over moderate 2-of-4. If vacancies unfilled by oral deadline June 30, adjust toward 0.50.
No launch announcement 29 days post-Q1 earnings. Month 17 post-facility-acquisition within 18–24 month base rate. [WaPo factory tour](https://www.washingtonpost.com/health/2026/05/24/weight-loss-compounder-hims-hers-is-shifting-wellness-longevity/) May 24 centers Aug–Nov timeline. [OneTwenty](https://onetwenty.com/blog/peptide-companies) now live as first non-Hims peptide DTC at scale — 30-day regulatory-response window is new leading indicator.
No new adverse events. Post-ADA / pre-PCAC media window (June 9 – July 22) is now the highest-probability period for peptide safety features. Health media bandwidth freed from ADA. PCAC deadline creates editorial urgency. 296 days to resolution.
No new peptide DTC affiliate programs. First-party: Katalys $349 (single Gala Health conversion), clicks −51% WoW. GSC impressions −50%, clicks −60%, position 19.2. Fifth consecutive declining week. GLP-1 CPA dominance ($260 vs $8–40) structural. compound-peptide-property-live: DORMANT QUEUE. Twenty-fourth consecutive flag. Not deliberated. OPERATOR: resolve TRUE in resolutions.tsv and retire.
Resolutions & upcoming
No forecasts resolved.
Upcoming: - T-15 Medicare Bridge reassessment (June 16, 7 days) — prior auth form released, canceling 0.78 escalation trigger. Reassess remaining operational gaps. - CMS Spring 2026 guidance deadline (June 20, 11 days) - PCAC oral presentation deadline (June 30, 21 days) — leading indicator for stakeholder engagement. - Medicare Bridge launch (July 1, 22 days) - bpc157-pcac-2026 / pcac-july-multi-peptide (July 23, 44 days) — PCAC Day 1.
How Barque got smarter today
- Pre-commitment framework validated. The T-30 → T-15 escalation ladder for medicare-glp1-bridge-uptake worked as designed. The prior auth form arrived between triggers, canceling the June 16 escalation. This is the first clean test of the pre-commitment framework and it prevented unnecessary probability drift. Codifying: pre-commitments with conditional escalation triggers are operationally superior to daily ad-hoc reassessment for slow-moving institutional signals.
- Clinical criteria as demand filter. The prior auth form reveals that the Bridge is narrower than "14M Medicare beneficiaries with obesity." The requirement for OSA, MASH, T2D, or CVD means the eligible population is smaller but more medically motivated. Future Medicare program enrollment estimates should model the eligibility-filter separately from administrative friction — they're independent constraints.
- glp1picks SEO decline now at five weeks. GSC impressions 1,755 this week, down from 3,500+ three weeks ago. This crosses from "fluctuation" to "structural." The diagnosis work order (`glp1picks-research-traffic-decline-may2026`) needs execution before the traffic floor makes revenue recovery mathematically difficult. Flagging as meta-concern: Ra can track the forecast, but the product needs operator attention.
- Sources sampled. Tier 1: FDA (PCAC roster, calendar), CMS (Bridge prior auth form, provider pages, MLN Connects), CNBC, Pharmacy Times, HCPLive. Tier 2 (rotated): OneTwenty, AJMC, Obesity Medicine Association, NCOA, DVM360. Tier 3: none today.